Actos

Type: Product

Name: Actos

First reported 2 hours ago - Updated 2 hours ago - 1 reports

Positive late-stage results for fasiglifam

Takeda's recently announced positive late-stage results for new type 2 diabetes drug, fasiglifam, has prompted excitement within the industry and raised hopes of reviving Takeda's diabetes treatment business, following last year's patent expiration of ... [Published Hospital Pharmacy Europe - 2 hours ago]

Entities: Drugs, Diabetes, Actos, Valentina, Patent

First reported May 23 2013 - Updated May 23 2013 - 1 reports

Aussies join Actos class action

An Australian law firm has lodged a claim in the US as part of a class action against the makers of diabetes drug Actos, which researchers say increases the risk of bladder cancer.Pioglitazone, the drug’s active component, is currently the subject of ... [Published Oncology Update - May 23 2013]

Entities: Actos, Bladder Cancer, Class Action, Drugs, Maurice Blackburn

First reported May 23 2013 - Updated May 23 2013 - 1 reports

LawyersandSettlements.com Provides Update on Diabetes Drug Lawsuits...

As diabetes drug lawsuits involving Actos, Januvia and Byetta move forward, LawyersandSettlements.com speaks with attorney Ben Stewart of Stewart Law PLLC for an update on the litigation. Although designed to treat Type 2 diabetes, some medications have ... [Published PRWeb - May 23 2013]

Entities: Byetta, Ben Stewart, Actos, Lawsuit

First reported May 21 2013 - Updated May 21 2013 - 1 reports

Australian who developed cancer from diabetes drug to fight US pharmaceuticals

AN AUSTRALIAN patient who developed bladder cancer after taking type 2 diabetes medication pioglitazone (Actos, Eli Lilly) for almost two years has been added to legal action taking place in the US against two pharmaceutical companies.Australian law firm ... [Published Medical Observer - May 21 2013]

Entities: Actos, Bladder Cancer, Drugs

First reported May 20 2013 - Updated May 20 2013 - 2 reports

Australians to join diabetes drug suit

Diabetes: More than 1.7 million prescriptions for the drug have been filled in Australia over the past four years. Australian victims of a popular diabetes drug that has been linked to bladder cancer will join a US class action suing the makers of the ... [Published The Sydney News - May 20 2013]

Entities: Diabetes, Drugs, Maurice Blackburn, Bladder Cancer, Class Action

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Takeda's diabetes drug fasiglifam shines in Phase III

Takeda Pharmaceutical Co has presented positive late-stage data on a new diabetes compound called fasiglifam.The company announced results of a Phase III trial at the Japan Diabetes Society meeting in Kumamoto, which show that 25mg and 50mg oral fasiglifam, ... [Published Pharma Times - May 20 2013]

Entities: Diabetes, Phase III, Actos, Glycated Hemoglobin

First reported May 19 2013 - Updated May 19 2013 - 3 reports

Actos Lawyers at Bernstein Liebhard LLP Note Issuance of New Case Management Order in Federal Actos Bladder Cancer Litigation

Actos lawsuit claims continue to move forward in a federal litigation now underway in U.S. District Court, Western District of Louisiana. According to a Case Management Order dated May 3rd, the Court has modified the litigation’s Bellwether Nomination ... [Published Bio-Medicine - May 19 2013]

Entities: Actos, Bladder Cancer, Litigation, Bernstein Liebhard LLP

First reported May 17 2013 - Updated May 17 2013 - 1 reports

Court Overturns $6.5M Verdict In First Actos Trial

Soon after a jury awarded $6.5 million to a California man who claimed the diabetes drug Actos caused him to develop bladder cancer, a court erased the verdict.Jack Cooper , 79, on April 26 won the award against Actos maker Takeda Pharmaceuticals. His ... [Published JD Supra - May 17 2013]

Entities: Actos, Takeda Pharmaceutical Co Ltd, Bladder Cancer, Michael Miller, Verdict

First reported May 14 2013 - Updated May 15 2013 - 3 reports

NZers invited to sue over diabetes drug

New Zealanders who've developed bladder cancer after taking a drug to treat type-two diabetes are being urged to join a group lawsuit against the drug's manufacturer.The drug is called Actos, and was prescribed to thousands of patients between 2001 and ... [Published 3 News - May 15 2013]

Entities: Bladder Cancer, Drugs, Takeda Pharmaceutical Co Ltd, Peter Marshall

First reported May 01 2013 - Updated May 02 2013 - 4 reports

DrugRisk Update: Jury Awards Bladder Cancer Victim $6.5 Million in Actos Lawsuit

The DrugRisk Resource Center is the Web’s largest source for information on prescription drug warnings, side effects and legal news. Visit The diabetes drug safety advocates at DrugRisk.com are announcing new information on the site for patients who have ... [Published PRWeb - May 02 2013]

Entities: Actos, Bladder Cancer, Lawsuit, Drugs

First reported Apr 29 2013 - Updated Apr 30 2013 - 4 reports

Plaintiff Wins First Actos Bladder Cancer Trial

- Apr. 30, 2013 - FORT LAUDERDALE, Fla. -- In the first Actos bladder cancer case to be tried, the jury awarded plaintiff, Jack Cooper, $6.5 million in damages against Actos manufacturer, Takeda Pharmaceutical of Japan. Plaintiff claimed that Takeda failed ... [Published Prlog - Apr 30 2013]

Entities: Actos, Bladder Cancer, Takeda Pharmaceutical Co Ltd, Plaintiff

First reported Apr 29 2013 - Updated Apr 30 2013 - 3 reports

Actos Bladder Cancer Lawsuit Update: Plaintiff Awarded $6.5 Million,...

is offering a response to the results of the first Actos trial, which concluded with a Los Angeles jury awarding $6.5 million to the Plaintiff, who charged that Takeda Pharmaceutical had failed to adequately warn consumers that its diabetes drug could ... [Published PRWeb - Apr 30 2013]

Entities: Actos, Bladder Cancer, Plaintiff, Takeda Pharmaceutical Co Ltd

Quotes

"We are entering an era in the diabetes market where the first-in-class drugs start in many ways to resemble 'me-too' drugs, despite their novel mechanisms of action. With some of the diabetes drugs going off patent, the prospect for future diabetes blockbusters becomes even bleaker due to eventual generic competition to the former blockbusters, and consequently, even more pronounced cost-effectiveness issues" says Dr Gburcik

Positive late-stage results for fasiglifam [Published Hospital Pharmacy Europe - 2 hours ago]

...Stryker metal hip implants clear, concise answers to their questions, including why the implants are failing and their legal rights and remedies? "We wish to provide patients with the recalled Stryker metal hip implants clear, concise answers to their questions, including why the implants are failing and their legal rights and remedies" stated Fleishman

Stryker Metal Hip Recall: Lieff Cabraser Provides Answers to Hip Replacement Patients [Published EON - May 22 2013]

"In accordance with our strict internal processes, which align with our regulatory obligations, we continuously monitor and notify regulatory authorities of adverse events reported using any of our medicines" the spokesperson said

Australian who developed cancer from diabetes drug to fight US pharmaceuticals [Published Medical Observer - May 21 2013]

...He noted that "it is a novel glucose dependent insulin secretagogue with low risk of hypoglycaemia"

Takeda's diabetes drug fasiglifam shines in Phase III [Published Pharma Times - May 20 2013]

More Content

sort by: Date \| Relevance
Positive late-stage results for fasiglifam [Published Hospital Pharmacy Europe - 2 hours ago]
VenEconomía: El Silencio de los Cómplices [Published Latin American Herald Tribune - 19 hours ago]
Aussies join Actos class action [Published Oncology Update - May 23 2013]
LawyersandSettlements.com Provides Update on Di... [Published PRWeb - May 23 2013]
Orexigen Therapeutics' CEO Presents at 2013 UBS... [Published Seeking Alpha - May 22 2013]
Stryker Metal Hip Recall: Lieff Cabraser Provid... [Published EON - May 22 2013]
Potential Lawsuit: Diabetes Medication Lawsuits [Published Lawyers & Settlements - May 21 2013]
Australian who developed cancer from diabetes d... [Published Medical Observer - May 21 2013]
Takeda's diabetes drug fasiglifam shines in Pha... [Published Pharma Times - May 20 2013]
Australians to join diabetes drug suit [Published The Sydney News - May 20 2013]
Australians to join multi-million dollar diabet... [Published Sydney Morning Herald - May 20 2013]
Actos Lawyers at Bernstein Liebhard LLP Note Is... [Published Bio-Medicine - May 19 2013]
Actos Lawyers at Bernstein Liebhard LLP Note Is... [Published PRWeb - May 19 2013]
NZ diabetes patients could join lawsuit [Published MSN New Zealand - May 19 2013]
Court Overturns $6.5M Verdict In First Actos Trial [Published JD Supra - May 17 2013]
Drug Discovery News: Facing the Patent Cliff He... [Published Baker Botts - May 17 2013]
Wright Medical Hip Lawsuit Update: New Video In... [Published Business Wire - May 17 2013]
Human medicines European Public Assessment Repo... [Published Pending EC decisions and European Public Assess ... - May 16 2013]
Human medicines European Public Assessment Repo... [Published Pending EC decisions and European Public Assess ... - May 16 2013]
More out of state plaintiffs sue Takeda over Ac... [Published Madison County Record - May 16 2013]
Diabetes drugs market will reach $55.3bn in 201... [Published Prlog - May 16 2013]
Kalamazoo Company Announces New Drug Target For... [Published CBS Detroit - May 16 2013]
Metabolic Solutions Development Company announc... [Published PR Newswire - May 15 2013]
Metabolic Solutions Development Company announc... [Published TickerTech.com - May 15 2013]
LabStyle Innovations - Glucose Monitoring For T... [Published Seeking Alpha - May 15 2013]
NZers invited to sue over diabetes drug [Published 3 News - May 15 2013]
Facing the patent cliff head-on [Published Drug Discovery News - May 15 2013]
Rx price check: Blockbuster generics vary widely [Published KSAT 12 - May 14 2013]
Diabetes Drug Actos Caused Bladder Cancer and W... [Published Bio-Medicine - May 14 2013]
Diabetes Drug Actos Caused Bladder Cancer and W... [Published Individual.com - May 14 2013]